Latest Isis Stories

CARLSBAD, Calif., Aug. 30, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the publication of two papers in the journal Cell demonstrating that single-stranded short interfering RNA (ss-siRNA) molecules distributed broadly, activated the RNA interference (RNAi) pathway and reduced expression of targeted genes in animal models. The RNAi pathway is a mechanism that can be used to inhibit expression of genes. The RNAi pathway has typically been engaged by...

CARLSBAD, Calif., Aug. 30, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2012 Stifel Nicolaus Healthcare Conference on Wednesday, September 5, 2012 at 11:30 a.m. ET in Boston. In addition, Isis will participate in the Biotech Panel hosted by Stephen Willey scheduled on Wednesday, September 5, 2012 at 9:10 a.m. ET. A live audio webcast of the presentation and...

CARLSBAD, Calif., Aug. 28, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $1.4 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) as its portion of the upfront fees in Alnylam's recently announced collaboration in the field of agriculture. In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments. This transaction further emphasizes the value of Isis' innovation and the...

CARLSBAD, Calif., Aug. 27, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: KYNAMRO(TM) data presented at the ESC Congress 2012 When: Wednesday, August 29th at 10:00 a.m. ET /7:00 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our Web...

CARLSBAD, Calif., Aug. 13, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has delivered a notice of redemption relating to all of its outstanding 2 5/8% Convertible Subordinated Notes due 2027 (the "2027 Notes") at a redemption price of 100.75% of the principal amount thereof. As of August 13, 2012, $162,500,000 aggregate principal amount of the 2027 Notes was outstanding. The 2027 Notes will be redeemed on September 12, 2012 unless earlier...

CARLSBAD, Calif., Aug. 9, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Canaccord Genuity 32(nd) Annual Growth Healthcare Conference on Thursday, August 16, 2012 at 11:00 a.m. ET in Boston. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the...

CARLSBAD, Calif., Aug. 8, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of its offering of $201.25 million aggregate principal amount of Convertible Senior Notes due 2019 (the "Convertible Notes") in a private placement, including $26.25 million aggregate principal amount of the Convertible Senior Notes due 2019 being sold pursuant to the exercise in full of the initial purchasers' over-allotment option. The sale of the Convertible Notes is...

CARLSBAD, Calif., Aug. 6, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer, subject to market and other considerations, $175.0 million aggregate principal amount of Convertible Senior Notes due 2019 (the "Convertible Notes") in a private placement. Isis also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $26.25 million aggregate principal amount of the...

CARLSBAD, Calif., Aug. 6, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma net operating income of $6.2 million for the three months ended June 30, 2012 and a pro forma net operating loss (NOL) of $10.0 million for the six months ended June 30, 2012 compared to a pro forma NOL of $11.6 million and $24.9 million for the same periods in 2011. The significant improvement in the Company's operating results was driven primarily by the $25 million...

CARLSBAD, Calif., Aug. 3, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has successfully completed a pre-approval inspection of its manufacturing facility located in Carlsbad, California. As part of the inspection, the European Medicines Agency (EMA) conducted an extensive review of Isis' manufacturing facility and processes and Isis' Good Manufacturing Practices (GMP) Quality systems to ensure product manufactured is of appropriate and...